Seattle Genetics (SGEN) Presents Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS (Brentuximab Vedotin) in CD30-Expressing Cutaneous T-Cell Lymphoma
Tweet Send to a Friend
Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted updated results from the phase 3 ALCANZA clinical trial evaluating ADCETRIS (brentuximab vedotin) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
